Intrinsic Value of S&P & Nasdaq Contact Us

Nephros, Inc. NEPH NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
76/100
4/7 Pass
SharesGrow Intrinsic Value
$3.65
+17.6%

Nephros, Inc. (NEPH) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.

Analysts estimate Earnings Per Share (EPS) of $0.01 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $0.01 vs est $0.01 (missed -30%). 2025: actual $0.11 vs est $0.11 (beat +0%). Analyst accuracy: 79%.

NEPH Analyst Ratings

Buy
4
Ratings
4 Buy
Based on 4 analysts giving stock ratings to Nephros, Inc. in the past 3 months
Rating breakdown
Buy
4 100%
100%
Buy
4 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — NEPH

79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual $0.01 vs Est $0.01 ▼ 42.9% off
2025 Actual $0.11 vs Est $0.11 ▼ 0.0% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is improving.

Revenue Estimates — NEPH

99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.014B vs Est $0.014B ▼ 0.1% off
2025 Actual $0.019B vs Est $0.019B ▲ 1.5% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message